

Trying 9351006...Open

Welcome to STN International! Enter x:x

LOGINID:ssspta1208dxj

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 Dec 18 Retrieve Abbreviations Automatically with SET
 ABBREVIATION in the Derwent World Patents Index
 NEWS 3 Dec 19 Announcing STN Express 4.1 with Discover!
 NEWS 4 Jan 5 VITIS File Segment Removed from FSTA Database
 NEWS 5 Jan 5 TIFF Images Added to CAOLD File
 NEWS 6 Jan 13 1998 Online Changes for Derwent Customers
 NEWS 7 Jan 19 The International Road and Transport Database, IRRD.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:22:59 ON 03 FEB 1998

=> fil bioslis medline uspatful embase caplus

'BIOSLIS' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):biosis medline uspatful embase caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.30	0.30

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 13:23:56 ON 03 FEB 1998

COPYRIGHT (C) 1998 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 13:23:56 ON 03 FEB 1998

FILE 'USPATFULL' ENTERED AT 13:23:56 ON 03 FEB 1998

CA INDEXING COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

BEST AVAILABLE COPY

FILE 'EMBASE' ENTERED AT 13:23:56 ON 03 FEB 1998
COPYRIGHT (C) 1998 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 13:23:56 ON 03 FEB 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

=> s polymer?

4 FILES SEARCHED...
L1 1734572 POLYMER?

=> s l1 and imag?

L2 72912 L1 AND IMAG?

=> s l2 and (chelate? or ligand?)

L3 5894 L2 AND (CHELATE? OR LIGAND?)

=> s l3 and cell?

1 FILES SEARCHED...
2 FILES SEARCHED...
4 FILES SEARCHED...
L4 4545 L3 AND CELL?

=> s l1 and contrast?

L5 100244 L1 AND CONTRAST?

=> s l4 and l5

L6 2297 L4 AND L5

=> s l6 and (polyamine? or spermidine? or polylysine?)

L7 648 L6 AND (POLYAMINE? OR SPERMIDINE? OR POLYLYSINE?)

=> s l7 aznd (polynucleo? or dna or nucleic or oligonucleo? or deoxyribonucleic)

MISSING OPERATOR L7 AZND

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l7 and (polynucleo? or dna or nucleic or oligonucleo? or deoxyribonucleic)

L8 140 L7 AND (POLYNUCLEO? OR DNA OR NUCLEIC OR OLIGONUCLEO? OR DEOXYRIBONUCLEIC)

=> s l8 and target?

L9 113 L8 AND TARGET?

=> s 19 and deliver?

L10 83 L9 AND DELIVER?

=> s 110 and uptake?

L11 65 L10 AND UPTAKE?

=> s 111 and receptor?

L12 55 L11 AND RECEPTOR?

=> s 112 and hydrophob?

L13 39 L12 AND HYDROPHOB?

=> d ibib ab 1-

YOU HAVE REQUESTED DATA FROM 39 ANSWERS - CONTINUE? Y/(N):y

L13 ANSWER 1 OF 39 USPATFULL
 ACCESSION NUMBER: 1998:9367 USPATFULL
 TITLE: Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein
 INVENTOR(S): Wickham, Thomas J., Potomac, MD, United States
 Kovesdi, Iare, Rockville, MD, United States
 Roelvvink, Petrus W., Gaithersburg, MD, United States
 Brough, Douglas E., Otney, MD, United States
 McVey, Duncan L., Derwood, MD, United States
 Bruder, Joseph T., Frederick, MD, United States
 GenVec, Inc., Rockville, MD, United States (U.S. corporation)
 PATENT ASSIGNEE(S):

	NUMBER	DATE
PATENT INFORMATION:	US 5712136	980127
APPLICATION INFO.:	US 96-634060	960417 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 94-303162, filed on 8 Sep 1994, now patented, Pat. No. US 5559099	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Elliott, George G.	
ASSISTANT EXAMINER:	Schwartzman, Robert	
LEGAL REPRESENTATIVE:	Leydig, Voit & Mayer, Ltd.	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	3142	
AB	A method of introducing an adenovirus into a cell that comprises a particular cell surface binding site, as well as a chimeric adenovirus penton base protein and recombinant adenoviral vector comprising the chimeric adenovirus penton base protein for use in the method, are provided.	

L13 ANSWER 2 OF 39 USPATFULL (Continued)
 genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

L13 ANSWER 2 OF 39 USPATFULL
 ACCESSION NUMBER: 1998:6923 USPATFULL
 TITLE: 17q-linked breast and ovarian cancer susceptibility gene
 INVENTOR(S): Skolnick, Mark H., Salt Lake City, UT, United States
 Goldgar, David E., Salt Lake City, UT, United States
 Miki, Yoshio, Salt Lake City, UT, United States
 Svenson, Jeff, Salt Lake City, UT, United States
 Kamb, Alexander, Salt Lake City, UT, United States
 Harshman, Keith D., Salt Lake City, UT, United States
 Shattuck-Eidens, Donna M., Salt Lake City, UT, United States
 Tavtigian, Sean V., Salt Lake City, UT, United States
 Wiseman, Roger W., Durham, NC, United States
 Futreal, P. Andrew, Durham, NC, United States
 Myriad Genetics, Inc., Salt Lake City, UT, United States (U.S. corporation)
 University of Utah Research Foundation, Salt Lake City, UT, United States (U.S. corporation)
 The United States of America as represented by the Secretary of Health and Human Services, Technology Transfer Office, Washington, DC, United States (U.S. government)
 PATENT ASSIGNEE(S):

	NUMBER	DATE
PATENT INFORMATION:	US 5710001	980120
APPLICATION INFO.:	US 95-487002	950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 95-409305, filed on 24 Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US 94-348824, filed on 29 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-308104, filed on 16 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-300266, filed on 2 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-289221, filed on 12 Aug 1994, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Jones, W. Gary	
ASSISTANT EXAMINER:	Rees, Dianne	
LEGAL REPRESENTATIVE:	Venable, Baetjer, Howard & Civiletti, LLP	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	4756	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	AB The present invention relates generally to the field of human	

L13 ANSWER 3 OF 39 USPATFULL
 ACCESSION NUMBER: 1998:6921 USPATFULL
 TITLE: Linked breast and ovarian cancer susceptibility gene
 INVENTOR(S): Shattuck-Eidens, Donna M., Salt Lake City, UT, United States
 Simard, Jacques, St. Augustin de Desmaures, Canada
 Durocher, Francine, Ste-Foy, Canada
 Emi, Mitsuru, Tokyo, Japan
 Nakamura, Yusuke, Yokohama, Japan
 Myriad Genetics Inc., Salt Lake City, UT, United States (U.S. corporation)
 Centre de Recherche du Chul, Sainte-Foy, Canada (non-U.S. corporation)
 Cancer Institute, Tokyo, Japan (non-U.S. corporation)
 PATENT ASSIGNEE(S):

	NUMBER	DATE
PATENT INFORMATION:	US 5709999	980120
APPLICATION INFO.:	US 95-483553	950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 95-409305, filed on 24 Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US 94-348824, filed on 29 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-308104, filed on 16 Sep 1994 which is a continuation-in-part of Ser. No. US 94-300266, filed on 2 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-289221, filed on 12 Aug 1994, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Jones, W. Gary	
ASSISTANT EXAMINER:	Rees, Dianne	
LEGAL REPRESENTATIVE:	Venable, Baetjer, Howard & Civiletti, LLP	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	5069	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	AB	

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein

L13 ANSWER 3 OF 39 USPATFULL (Continued)

mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

L13 ANSWER 4 OF 39 USPATFULL

ACCESSION NUMBER: 1998:1671 USPATFULL
 TITLE: Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
 INVENTOR(S): Bally, Marcel B., Bowen Island, Canada
 Zhang, Yuan-Peng, Vancouver, Canada
 Reimer, Dorothy L., Vancouver, Canada
 Wheeler, Jeffery J., Richmond, Canada
 PATENT ASSIGNEE(S): Inex Pharmaceuticals Corporation, Vancouver, Canada (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5705385	980106
APPLICATION INFO.:	US 95-485458	950607 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Ketter, James	
ASSISTANT EXAMINER:	Yucel, Irem	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	1318	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel, hydrophobic lipid-nucleic acid complexes. The complexes are charge-neutralized and contain the nucleic acid in a non-condensed form. Manipulation of these complexes in either detergent-based or organic solvent-based systems leads to particle formation. Thus, the present invention also provides methods of preparing lipid-nucleic acid particles which are useful for the therapeutic delivery of nucleic acids. The particles are constructed via hydrophobic lipid-nucleic acid intermediates (or complexes). Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the nucleic acid forms a particle with lipids and is protected from degradation. The particles thus formed are suitable for use in intravenous nucleic acid transfer as they are stable in circulation, of a size required for pharmacodynamic behavior resulting in access to extravascular sites and target cell populations.

L13 ANSWER 5 OF 39 USPATFULL

ACCESSION NUMBER: 1998:1480 USPATFULL
 TITLE: Compositions of lipids and stabilizing materials
 INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
 PATENT ASSIGNEE(S): ImRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5705187	980106
APPLICATION INFO.:	US 95-417238	950405 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 94-307305, filed on 16 Sep 1994 And Ser. No. US 93-160232, filed on 30 Nov 1993, now patented, Pat. No. US 5542935, issued on 6 Aug 1996 which is a continuation-in-part of Ser. No. US 93-159674, filed on 30 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-76250, filed on 11 Jun 1993, now patented, Pat. No. US 5580575 which is a continuation-in-part of Ser. No. US 91-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446, issued on 20 Jul 1993 And Ser. No. US 91-716899, filed on 18 Jun 1991, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 90-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499, issued on 18 Feb 1992 which is a continuation-in-part of Ser. No. US 89-455707, filed on 22 Dec 1989, now abandoned, said Ser. No. US -307305 which is a continuation-in-part of Ser. No. US 93-159687, filed on 30 Nov 1993, now patented, Pat. No. US 5585112 which is a continuation-in-part of Ser. No. US 93-160232, filed on 30 Nov 1993, now patented, Pat. No. US 5542935, issued on 6 Aug 1996 which is a continuation-in-part of Ser. No. US 93-76239, filed on 11 Jun 1993, now patented, Pat. No. US 5469854, issued on 28 Nov 1995 which is a continuation-in-part of Ser. No. US -717084 And Ser. No. US -716899, each Ser. No. US - which is a continuation-in-part of Ser. No. US -569828 which is a continuation-in-part of Ser. No. US -455707	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP	
NUMBER OF CLAIMS:	220	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2239	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising, in an aqueous carrier, a lipid and a material which is capable of stabilizing the composition. The stabilizing material is associated non-covalently with said lipid and is present in an amount sufficient to coat the lipid but insufficient to raise the viscosity of the composition. The compositions are particularly suitable for use in diagnostic applications, including ultrasound. The compositions can take the

L13 ANSWER 5 OF 39 USPATFULL (Continued)

form of vesicular compositions, such as micelles and liposomes.

L13 ANSWER 6 OF 39 USPATFULL
 ACCESSION NUMBER: 97:117676 USPATFULL
 TITLE: Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
 INVENTOR(S): Goldenberg, David M., Mendham, NJ, United States
 PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

NUMBER	DATE
US 5698178	971216

PATENT INFORMATION: US 5698178 971216
 APPLICATION INFO.: US 96-629387 960408 (8)
 RELATED APPLN. INFO.: Division of Ser. No. US 94-286430, filed on 5 Aug 1994
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Chan, Christina Y.
 ASSISTANT EXAMINER: Cech, Emma
 LEGAL REPRESENTATIVE: Foley & Lardner
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2203

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.

L13 ANSWER 7 OF 39 USPATFULL
 ACCESSION NUMBER: 97:112310 USPATFULL
 TITLE: Linked breast and ovarian cancer susceptibility gene
 INVENTOR(S): Shattuck-Eidens, Donna M., Salt Lake City, UT, United States
 Sinaard, Jacques, Quebec, Canada
 Durocher, Francine, Ste-Foy, Canada
 Emi, Mitsuuru, Tokyo, Japan
 Nakamura, Yusuke, Yokohama, Japan
 Myriad Genetics, Inc., Salt Lake City, UT, United States (U.S. corporation)
 Centre de Recherche du Chul, Sainte-Foy, Canada (non-U.S. corporation)
 Cancer Institute, Tokyo, Japan (non-U.S. corporation)

NUMBER	DATE
US 5693473	971202

PATENT INFORMATION: US 5693473 971202
 APPLICATION INFO.: US 95-480784 950607 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 95-409305, filed on 24 Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US 94-348824, filed on 29 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-308104, filed on 9 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-300266, filed on 2 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-289221, filed on 12 Aug 1994, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Jones, W. Gary
 ASSISTANT EXAMINER: Rees, Dianne
 LEGAL REPRESENTATIVE: Venable, Baetjer, Howard & Civiletti, LLP
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 19 Drawing Figure(s); 18 Drawing Page(s)
 LINE COUNT: 4831

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis

L13 ANSWER 7 OF 39 USPATFULL (Continued)
 and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

L13 ANSWER 8 OF 39 USPATFULL
 ACCESSION NUMBER: 97:104602 USPATFULL
 TITLE: Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
 INVENTOR(S): Goldenberg, David M., Mendham, NJ, United States
 PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

NUMBER	DATE
US 5686578	971111

PATENT INFORMATION: US 5686578 971111
 APPLICATION INFO.: US 94-286430 940805 (8)
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Foley & Lardner
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2133

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.

L13 ANSWER 9 OF 39 USPATFULL
 ACCESSION NUMBER: 97:81134 USPATFULL
 TITLE: Isolation of biological materials
 INVENTOR(S): Kausch, Albert P., Stonington, CT, United States
 Narayanswami, Sandya, Bar Harbor, ME, United States
 PATENT ASSIGNEE(S): Dekalb Genetics Corp., Mystic, CT, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5665582	970909
APPLICATION INFO.:	US 94-229288	940418 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 90-605852, filed on 29 Oct 1990, now abandoned which is a continuation of Ser. No. US 93-146434, filed on 29 Oct 1993, now patented, Pat. No. US 5508164	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fleisher, Mindy	
ASSISTANT EXAMINER:	Ketter, James	
LEGAL REPRESENTATIVE:	Arnold, White & Durkee	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	43 Drawing Figure(s); 31 Drawing Page(s)	
LINE COUNT:	3696	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the isolation and sorting of biological materials has been developed. Biological material includes chromosomes, segments of chromosomes, cell organelles, or other minute cellular components. The biological material is separated from the cellular milieu, if necessary, and anchored to a support. Examples of a support are glass coverslips, glass or polymer beads. The anchoring is by means of a reversible polymer and cross-linking system. The supported biological material may then be labelled with compositions capable of binding to said material, and with magnetic particles. Examples of the binding material include nucleic acid probes and antibodies. An example of the antibodies would be those directed to histones. Other labels, for example, fluorescein-biotin-avidin may be used. The material may be released from the support and sorted by a magnetic force. This method is an alternative to flow cytometry and presents numerous advantages in terms of time, resolution, purity, and preservation of the structure of the biological material during isolation and separation.

L13 ANSWER 10 OF 39 USPATFULL
 ACCESSION NUMBER: 97:78170 USPATFULL
 TITLE: Compositions and methods for cancer immunotherapy
 INVENTOR(S): Barber, Jack R., San Diego, CA, United States
 Jolly, Douglas J., Laucadia, CA, United States
 Respass, James G., San Diego, CA, United States
 Chiron Viagene, Inc., San Diego, CA, United States
 PATENT ASSIGNEE(S): States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5662896	970902
APPLICATION INFO.:	US 93-32846	930317 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 92-965084, filed on 22 Oct 1992, now abandoned which is a continuation of Ser. No. US 90-586603, filed on 21 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 90-565606, filed on 10 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 89-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 88-170515, filed on 21 Mar 1988, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fleisher, Mindy	
ASSISTANT EXAMINER:	Railey, II, Johnny F.	
LEGAL REPRESENTATIVE:	Seed & Berry; Kruse, Norman J.; Blackburn, Robert P.	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	34 Drawing Figure(s); 22 Drawing Page(s)	
LINE COUNT:	2662	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for inhibiting the growth of selected tumors utilizing recombinant viral vectors. Briefly, within one aspect of the present invention, a method for inhibiting the growth of a selected tumor is provided comprising the step of directly administering to a warm-blooded animal a vector construct which directs the expression of at least one anti-tumor agent, such that the growth of said tumor is inhibited. Representative examples of anti-tumor agents include immune activators and tumor proliferation inhibitors.

L13 ANSWER 11 OF 39 USPATFULL
 ACCESSION NUMBER: 97:66028 USPATFULL
 TITLE: Human neutralizing monoclonal antibodies to human immunodeficiency virus
 INVENTOR(S): Burton, Dennis R., La Jolla, CA, United States
 Barbas, Carlos F., San Diego, CA, United States
 Lerner, Richard A., La Jolla, CA, United States
 PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5652138	970729
APPLICATION INFO.:	US 94-276852	940718 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 94-178302, filed on 6 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 92-954148, filed on 30 Sep 1992, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Budens, Robert D.	
LEGAL REPRESENTATIVE:	Fitting, Thomas	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	60 Drawing Figure(s); 56 Drawing Page(s)	
LINE COUNT:	5839	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes human monoclonal antibodies which immunoreact with and neutralize human immunodeficiency virus (HIV). Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell line for producing the monoclonal antibodies.

L13 ANSWER 12 OF 39 USPATFULL
 ACCESSION NUMBER: 97:42628 USPATFULL
 TITLE: Two-step pretargeting methods using improved biotin-active agent conjugates
 INVENTOR(S): Reno, John M., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 NeoRx Corporation, Seattle, WA, United States
 PATENT ASSIGNEE(S): (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5630996	970520
APPLICATION INFO.:	US 93-122979	930916 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 92-995381, filed on 23 Dec 1992, now abandoned And Ser. No. US 92-995383, filed on 23 Dec 1992, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 92-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Eisenschenk, Frank C.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 22 Drawing Page(s)	
LINE COUNT:	4768	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

L13 ANSWER 13 OF 39 USPATFULL
 ACCESSION NUMBER: 97:36156 USPATFULL
 TITLE: Clearing agents useful in pretargeting methods
 INVENTOR(S): Aworthy, Donald B., Brier, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States
 (U.S. corporation)

NUMBER	DATE
US 5624896	970429
US 95-462765	950605 (8)

PATENT INFORMATION: Continuation of Ser. No. US 93-163184, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 18
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
 LINE COUNT: 3943

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel clearing agents are provided which comprise biotin analog containing clearance-directing moieties. Preferably such clearance-directing moieties endogenously contain or a rederivatized to expose galactose and/or mannose residues.

L13 ANSWER 15 OF 39 USPATFULL
 ACCESSION NUMBER: 97:29572 USPATFULL
 TITLE: Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
 INVENTOR(S): Toback, F. Gary, Chicago, IL, United States
 Lieske, John C., Evanston, IL, United States
 PATENT ASSIGNEE(S): ARCH Development Corporation, Chicago, IL, United States (U.S. corporation)

NUMBER	DATE
US 5618917	970408
US 95-389005	950215 (8)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 92-995383, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Nucker, Christine M.
 ASSISTANT EXAMINER: Reeves, Julie E.
 LEGAL REPRESENTATIVE: Brinks Hofer Gilson & Lione
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
 LINE COUNT: 1623

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.

L13 ANSWER 14 OF 39 USPATFULL
 ACCESSION NUMBER: 97:36080 USPATFULL
 TITLE: Germ-line mutations in the MTS gene
 INVENTOR(S): Skolnick, Mark H., Salt Lake City, UT, United States
 Cannon-Albright, Lisa A., Salt Lake City, UT, United States
 Kamb, Alexander, Salt Lake City, UT, United States
 PATENT ASSIGNEE(S): University of Utah Research Foundation, Salt Lake City, UT, United States (U.S. corporation)
 Myriad Genetics, Inc., Salt Lake City, UT, United States (U.S. corporation)

NUMBER	DATE
US 5624819	970429
US 95-474177	950607 (8)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 94-251938, filed on 1 Jun 1994, now abandoned Ser. No. Ser. No. US 94-215087, filed on 18 Mar 1994, now abandoned And Ser. No. US 94-215086, filed on 18 Mar 1994, now abandoned, said Ser. No. US 94-251938, filed on 1 Jun 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-227369, filed on 14 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 94-214582, filed on 18 Mar 1994, now abandoned

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Wax, Robert A.
 ASSISTANT EXAMINER: Lau, Kawai
 LEGAL REPRESENTATIVE: Venable, Baetjer, Howard & Civiletti, LLP
 NUMBER OF CLAIMS: 9
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 30 Drawing Figure(s); 25 Drawing Page(s)
 LINE COUNT: 4016

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.

L13 ANSWER 16 OF 39 USPATFULL
 ACCESSION NUMBER: 97:27275 USPATFULL
 TITLE: Hexose derivatized human serum albumin clearing agents
 INVENTOR(S): Aworthy, Donald B., Brier, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	DATE
US 5616690	970401
US 93-133613	931008 (8)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 92-995383, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 2945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel clearing agents comprising hexose derivatized human serum albumin and ligand molecule(s) are provided. These clearing agents are useful in pretargeting methods to clear previously administered anti-ligand containing conjugates. Preferably, the hexose is mannose or galactose and the ligand and anti-ligand are respectively biotin and avidin or streptavidin.

L13 ANSWER 17 OF 39 USPATFULL
 ACCESSION NUMBER: 97:18284 USPATFULL
 TITLE: Biotinidase-resistant biotin-DOTA conjugates
 INVENTOR(S): Amworthy, Donald B., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 NeoRx Corporation, Seattle, WA, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5608060	970304
APPLICATION INFO.:	WO 9325240	931223
RELATED APPLN. INFO.:	US 95-351469	950221 (8)
	WO 93-US5406	930607
	950221	PCT 371 date
	950221	PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 92-995383, filed on 23 Dec 1992, now abandoned And a continuation-in-part of Ser. No. US 92-995381, filed on 23 Dec 1992, now abandoned, each Ser. No. US 92-89588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342, issued on 1 Feb 1994	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Eisenschek, Frank C.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 22 Drawing Page(s)	
LINE COUNT:	4732	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.	

L13 ANSWER 19 OF 39 USPATFULL
 ACCESSION NUMBER: 96:116123 USPATFULL
 TITLE: Method of preparing gas and gaseous
 INVENTOR(S): Ungert, Evan C., Tucson, AZ, United States
 Fritz, Thomas A., Tucson, AZ, United States
 Matsunaga, Terry, Tucson, AZ, United States
 Ramaswami, VaradaRajan, Tucson, AZ, United States
 Yellowhair, David, Tucson, AZ, United States
 Wu, Guanli, Tucson, AZ, United States
 InaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5585112	961217
APPLICATION INFO.:	US 93-159687	931130 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 93-160232, filed on 30 Nov 1993, now abandoned And a continuation-in-part of Ser. No. US 93-159674, filed on 30 Nov 1993, now abandoned, each Ser. No. US 93-76239, filed on 11 Jun 1993, now patented, Pat. No. US 5469854 which is a continuation-in-part of Ser. No. US 91-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 And Ser. No. US 91-716899, filed on 18 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 90-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499 which is a continuation-in-part of Ser. No. US 89-455707, filed on 22 Dec 1989, now abandoned, said Ser. No. US 91-717084 which is a continuation-in-part of Ser. No. US 90-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	3161	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.	

L13 ANSWER 18 OF 39 USPATFULL
 ACCESSION NUMBER: 97:17886 USPATFULL
 TITLE: Directed biodistribution of radiolabelled biotin using carbohydrate polymers
 INVENTOR(S): Gustavson, Linda M., Seattle, WA, United States
 Fritzberg, Alan R., Edmonds, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5607659	970304
APPLICATION INFO.:	US 95-482788	950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 93-12533, filed on 2 Feb 1993, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Hollinden, Gary E.	
ASSISTANT EXAMINER:	Chapman, Lara E.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, LLP	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1819	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention provides methods for directing the biodistribution of molecules that are not generally specifically excreted via the renal pathway to renal excretion. The methods employ conjugates or complexes containing a directed biodistribution molecule (DBM) and one or more bound molecules, wherein the biodistribution of the conjugate or complex is directed to renal excretion in vivo by the DBM component thereof.	

L13 ANSWER 20 OF 39 USPATFULL
 ACCESSION NUMBER: 96:111166 USPATFULL
 TITLE: Therapeutic drug delivery systems
 INVENTOR(S): Ungert, Evan C., Tucson, AZ, United States
 Fritz, Thomas A., Tucson, AZ, United States
 Matsunaga, Terry, Tucson, AZ, United States
 Ramaswami, VaradaRajan, Tucson, AZ, United States
 Yellowhair, David, Tucson, AZ, United States
 Wu, Guanli, Tucson, AZ, United States
 InaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5580575	961203
APPLICATION INFO.:	US 93-76250	930611 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 91-716899, filed on 18 Jun 1991, now abandoned And a continuation-in-part of Ser. No. US 91-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 which is a continuation-in-part of Ser. No. US 90-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499 which is a continuation-in-part of Ser. No. US 89-455707, filed on 22 Dec 1989, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 21 Drawing Page(s)	
LINE COUNT:	2932	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Therapeutic drug delivery systems comprising gas-filled microspheres comprising a therapeutic are described. Methods for employing such microspheres in therapeutic drug delivery applications are also provided. Drug delivery systems comprising gas-filled liposomes having encapsulated therein a drug are preferred. Methods of and apparatus for preparing such liposomes and methods for employing such liposomes in drug delivery applications are also disclosed.	

L13 ANSWER 21 OF 39 USPATFULL
 ACCESSION NUMBER: 96:108699 USPATFULL
 TITLE: Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
 INVENTOR(S): Domb, Abraham J., Efrat, Israel
 Gref, Ruxandra, Nancy, France
 Minamitake, Yoshiharu, Ota, Japan
 Paracchia, Maria T., Parma, Italy
 Langer, Robert S., Newton, MA, United States
 Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5578325	961126
APPLICATION INFO.:	US 94-265440	940624 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 94-210677, filed on 18 Mar 1994 which is a continuation-in-part of Ser. No. US 93-96370, filed on 23 Jul 1993	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Azpuru, Carlos	
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	1284	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Injectable particles are provided that are not rapidly cleared from the blood stream by the macrophages of the reticuloendothelial system, and that can be modified as necessary to achieve variable release rates or to target specific cells or organs as desired. The injectable particles can include magnetic particles or radiopaque materials for diagnostic imaging, biologically active molecules to be delivered to a site, or compounds for targeting the particles. Biodistribution experiments indicate that the injectable particles have a prolonged half-life in the blood compared to particles not containing poly(alkylene glycol) moieties on the surface.

L13 ANSWER 23 OF 39 USPATFULL
 ACCESSION NUMBER: 96:97025 USPATFULL
 TITLE: Texaphyrins and uses thereof
 INVENTOR(S): Magda, Darren, Cupertino, CA, United States
 Sessler, Jonathan L., Austin, TX, United States
 Iverson, Brent, Austin, TX, United States
 Jansen, Petra L., Austin, TX, United States
 Wright, Meredith, San Jose, CA, United States
 Mody, Tarak D., Sunnyvale, CA, United States
 Hemmi, Gregory W., Sunnyvale, CA, United States
 University of Texas, Austin, TX, United States (U.S. corporation)
 Pharmacyclics, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5567687	961022
APPLICATION INFO.:	US 94-310501	940921 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 93-112872, filed on 25 Aug 1993, now patented, Pat. No. US 5451576 And Ser. No. US 94-227370, filed on 14 Apr 1994 which is a continuation-in-part of Ser. No. US 93-75123, filed on 9 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-822964, filed on 21 Jan 1992, now patented, Pat. No. US 5252720, issued on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 91-771393, filed on 30 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 90-539975, filed on 18 Jun 1990, now patented, Pat. No. US 5162509, issued on 10 Nov 1992 which is a division of Ser. No. US 89-320293, filed on 6 Mar 1989, now patented, Pat. No. US 4935498, issued on 19 Jun 1990, said Ser. No. US -112872 which is a division of Ser. No. US -822964	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Raymond, Richard L.	
LEGAL REPRESENTATIVE:	Arnold, White & Durkee	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	28 Drawing Figure(s); 28 Drawing Page(s)	
LINE COUNT:	2828	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A texaphyrin having substituents containing ethoxy groups, methods for using texaphyrins in photodynamic therapy, and cleavage of a polymer of deoxyribonucleic acid are disclosed. The in vivo treatment of tumors and atherosclerosis is demonstrated using Lu(III)texaphyrin complexes. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.

L13 ANSWER 22 OF 39 USPATFULL
 ACCESSION NUMBER: 96:108662 USPATFULL
 TITLE: Three-step pretargeting methods using improved biotin-active agent
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Rano, John M., Brier, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 Neorx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5578287	961126
APPLICATION INFO.:	US 93-156614	931123 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 92-995383, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Elsenschenk, Frank C.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	2318	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.

L13 ANSWER 24 OF 39 USPATFULL
 ACCESSION NUMBER: 96:108648 USPATFULL
 TITLE: Biodegradable injectable particles for imaging
 INVENTOR(S): Gref, Ruxandra, Nancy, France
 Minamitake, Yoshiharu, Brookline, MA, United States
 Langer, Robert S., Newton, MA, United States
 Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5565215	961015
APPLICATION INFO.:	US 94-210677	940318 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 93-96370, filed on 23 Jul 1993	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Azpuru, Carlos	
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	1147	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Injectable nanoparticles or microparticles are provided that are not rapidly cleared from the blood stream by the macrophages of the reticuloendothelial system, and that can be modified as necessary to achieve variable release rates or to target specific cells or organs as desired. The terminal hydroxyl group of the poly(alkylene glycol) can be used to covalently attach onto the surface of the injectable particles biologically active molecules, including antibodies targeted to specific cells or organs, or molecules affecting the charge, lipophilicity or hydrophilicity of the particle. The surface of the particle can also be modified by attaching biodegradable polymers of the same structure as those forming the core of the injectable particles. The injectable particles include magnetic particles or radioopaque materials for diagnostic imaging.

L13 ANSWER 25 OF 39 USPATFULL
 ACCESSION NUMBER: 96:91025 USPATFULL
 TITLE: Polymeric microparticles containing agents for imaging
 INVENTOR(S): Cohen, Smadar, Petach-Tickva, Israel
 Andrianov, Alexander K., Belmont, MA, United States
 Wheatley, Margaret, Media, PA, United States
 Allcock, Harry R., State College, PA, United States
 PATENT ASSIGNEE(S): Langer, Robert S., Newton, MA, United States
 Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
 The Penn State Research Foundation, University Park, PA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5562099	961008
APPLICATION INFO.:	US 94-292522	940818 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 94-214860, filed on 18 Mar 1994 which is a continuation-in-part of Ser. No. US 94-182216, filed on 14 Jan 1994, now patented, Pat. No. US 5487390 which is a continuation-in-part of Ser. No. US 92-880248, filed on 8 May 1992, now patented, Pat. No. US 5308701 which is a division of Ser. No. US 90-593684, filed on 5 Oct 1990, now patented, Pat. No. US 5149543	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kulkosky, Peter F.	
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1256	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions, methods for preparing and methods of using contrast agent-filled polymeric microparticles for imaging are disclosed. In a preferred embodiment, air-encapsulating microparticles are formed by ionotropically gelling synthetic polyelectrolytes such as poly(carboxylatophenyl)phosphazene, poly(acrylic acid), poly(methacrylic acid) and methacrylic acid copolymers (Eudragit's) by contact with multivalent ions such as calcium ions. In the preferred embodiment, the average size of the microparticles is less than seven μm so that they are suitable for injection intravenously. The polymeric microparticles are stable to imaging and display high echogenicity, both in vitro and in vivo. Due to their in vivo stability their potential application is extended beyond vascular imaging to liver and renal diseases, fallopian tube diseases, detecting and characterizing tumor masses and tissues, and measuring peripheral blood velocity. The microparticles can

L13 ANSWER 26 OF 39 USPATFULL
 ACCESSION NUMBER: 96:75377 USPATFULL
 TITLE: Composition for introducing nucleic acid complexes into higher eucaryotic cells
 INVENTOR(S): Curjel, David T., Chapel Hill, NC, United States
 Birnstiel, Max L., Vienna, Austria
 Cotten, Matthew, Vienna, Austria
 Wagner, Ernst, Langenzerndorf, Austria
 Zatloukal, Kurt, Vienna, Austria
 Plank, Christian, Vienna, Austria
 Oberhauser, Berndt, Vienna, Austria
 Schmidt, Walter G. M., Vienna, Austria
 Boehringer Ingelheim International GmbH, Germany, Federal Republic of (non-U.S. corporation)
 Genentech, Inc., San Francisco, CA, United States (U.S. corporation)
 PATENT ASSIGNEE(S):

	NUMBER	DATE
PATENT INFORMATION:	US 5547932	960820
APPLICATION INFO.:	US 92-948357	920923 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 92-827103, filed on 30 Jan 1992, now abandoned Ser. No. Ser. No. US 91-768039, filed on 30 Sep 1991, now abandoned And Ser. No. US 92-937788, filed on 2 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-864759, filed on 7 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-827102, filed on 30 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 91-767788, filed on 30 Sep 1991, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Jones, W. Gary	
ASSISTANT EXAMINER:	Sisson, Bradley L.	
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.	
NUMBER OF CLAIMS:	75	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	78 Drawing Figure(s); 65 Drawing Page(s)	
LINE COUNT:	5851	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for the transfection of higher eucaryotic cells, comprising complexes of nucleic acid, a substance having an affinity for nucleic acid and optionally an internalizing factor, contains an endosomolytic agent, e.g. a virus or virus component, which may be conjugated. The endosomolytic agent, which is optionally part of the nucleic acid complex, is internalized into the cells together with the complex and releases the contents of the endosomes into the cytoplasm, thereby increasing the gene transfer capacity. Pharmaceutical preparations, transfection kits and methods for introducing nucleic acid into higher eucaryotic cells by treating the cells with the composition are also disclosed.

L13 ANSWER 25 OF 39 USPATFULL (Continued)
 optionally be linked with ligands that minimize tissue adhesion or that target the microparticles to specific regions.

L13 ANSWER 27 OF 39 USPATFULL
 ACCESSION NUMBER: 96:69985 USPATFULL
 TITLE: Therapeutic delivery systems related applications
 INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
 Fritz, Thomas A., Tucson, AZ, United States
 Matsunaga, Terry, Tucson, AZ, United States
 Ramaswami, Varadarajan, Tucson, AZ, United States
 Yellowhair, David, Tucson, AZ, United States
 Wu, Guanli, Tucson, AZ, United States
 PATENT ASSIGNEE(S): Inak.sub.X Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5542935	960806
APPLICATION INFO.:	US 93-160232	931130 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 93-159687, filed on 29 Nov 1993 And Ser. No. US 93-159674, filed on 29 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-76250, filed on 11 Jun 1993 which is a continuation-in-part of Ser. No. US 91-716899, filed on 18 Jun 1991, now abandoned And Ser. No. US 91-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 which is a continuation-in-part of Ser. No. US 90-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499 which is a continuation-in-part of Ser. No. US 89-455707, filed on 22 Dec 1989, now abandoned, said Ser. No. US -159687 which is a continuation-in-part of Ser. No. US -76250, said Ser. No. US -716899 which is a continuation-in-part of Ser. No. US -569828	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Jaworski, Francis	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	35	
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 23 Drawing Page(s)	
LINE COUNT:	4275	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Therapeutic delivery systems comprising gaseous precursor-filled microspheres comprising a therapeutic are described. Methods for employing such microspheres in therapeutic delivery applications are also provided. Therapeutic delivery systems comprising gaseous precursor-filled liposomes having encapsulated therein a contrast agent or drug are preferred. Methods of and apparatus for preparing such liposomes and methods for employing such liposomes in therapeutic delivery applications are also disclosed.

L13 ANSWER 28 OF 39 USPATFULL
 ACCESSION NUMBER: 96:68105 USPATFULL
 TITLE: Pretargeting methods and compounds
 INVENTOR(S): Yau, Eric K., Kirkland, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 NeoRx Corporation, Seattle, WA, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5541287	960730
APPLICATION INFO.:	US 94-345811	941122 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 93-156565, filed on 22 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 92-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342, issued on 1 Feb 1994	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Chan, Christina Y.
 ASSISTANT EXAMINER: Prickril, Benet
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 17 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 4365
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.

L13 ANSWER 30 OF 39 USPATFULL
 ACCESSION NUMBER: 96:53207 USPATFULL
 TITLE: Methods and compositions relating to sterol regulatory element binding proteins
 INVENTOR(S): Goldstein, Joseph L., Dallas, TX, United States
 Brown, Michael S., Dallas, TX, United States
 Briggs, Michael R., San Diego, CA, United States
 Wang, Xiaodong, Dallas, TX, United States
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5527690	960618
APPLICATION INFO.:	US 93-131365	931001 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 93-61697, filed on 13 May 1993 Ser. No. Ser. No. US 89-425852, filed on 20 Oct 1989, now patented, Pat. No. US 5256545 And Ser. No. US 87-33081, filed on 30 Mar 1987, now patented, Pat. No. US 5378603	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Guzo, David
 LEGAL REPRESENTATIVE: Arnold, White & Duckee
 NUMBER OF CLAIMS: 43
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 76 Drawing Figure(s); 67 Drawing Page(s)
 LINE COUNT: 5252
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A sterol regulatory element (SRE) binding protein (SREBP) which activates transcription from SREs, such as SRE-1 of the low density lipoprotein (LDL) receptor gene, is disclosed, as are DNA segments encoding SREBPs such as an SREBP-1 or SREBP-2. Also described are methods for using SREBP to promote SRE-mediated transcription and LDL receptor production in the presence of sterols, and screening assay for the identification of further agents with such properties. The SREBP and other agents may be used to reduce plasma cholesterol levels and to treat various medical problems associated with hypercholesterolemia.

L13 ANSWER 29 OF 39 USPATFULL
 ACCESSION NUMBER: 96:60430 USPATFULL
 TITLE: Amphipathic polychelating compounds and methods of use
 INVENTOR(S): Torchilin, Vladimir P., 41, 8th St., #3208, Charlestown, MA, United States 02129
 Trubetskoy, Vladimir S., 9 Morton Ter., Milton, MA, United States 02186
 Wolf, Gerald L., 5 Hawthorn Rd., Winchester, MA, United States 01890

	NUMBER	DATE
PATENT INFORMATION:	US 5534241	960709
APPLICATION INFO.:	US 93-96083	930723 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Hollinden, Gary E.	
LEGAL REPRESENTATIVE:	Fish & Richardson	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	805	

AB An amphipathic polychelating compound including a hydrophilic polymeric moiety having a main backbone and a plurality of reactive side groups, a lipid-soluble anchor linked to the N terminal of the polymeric moiety, and a plurality of chelating agents linked to the side groups of the polymeric moiety. The polychelating compounds are bound to liposomes or micelles for use as diagnostic and therapeutic agents.

L13 ANSWER 31 OF 39 USPATFULL
 ACCESSION NUMBER: 96:53043 USPATFULL
 TITLE: Dense star polymer conjugates
 INVENTOR(S): Tomalia, Donald A., Midland, MI, United States
 Wilson, Larry R., Beaverton, MI, United States
 Hedstrand, David M., Midland, MI, United States
 Tomlinson, Ian A., Midland, MI, United States
 Fazio, Michael J., Midland, MI, United States
 Kruper, Jr., William J., Sanford, MI, United States
 Kaplan, Donald A., Cincinnati, OH, United States
 Cheng, Roberta C., Midland, MI, United States
 Edwards, David S., Burlington, MA, United States
 Jung, Chu W., Arlington, MA, United States
 The Dow Chemical Company, Midland, MI, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5527524	960618
APPLICATION INFO.:	US 93-43198	930405 (8)
DISCLAIMER DATE:	20110816	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 91-654851, filed on 13 Feb 1991, now patented, Pat. No. US 5338532 which is a continuation-in-part of Ser. No. US 89-386049, filed on 26 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 87-87266, filed on 18 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 86-897455, filed on 18 Aug 1986, now abandoned	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Page, Thurman K.
 LEGAL REPRESENTATIVE: Kimble, Karen L.
 NUMBER OF CLAIMS: 114
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
 LINE COUNT: 3839
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Dense star polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried agricultural, pharmaceutical, or other material have been prepared. These conjugates have particularly advantageous properties due to the unique characteristics of the dendrimer.

L13 ANSWER 32 OF 39 USPATFULL
 ACCESSION NUMBER: 96:14715 USPATFULL
 TITLE: Monocrystalline iron oxide particles for studying biological tissues
 INVENTOR(S): Weissleder, Ralph, Somerville, MA, United States
 PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5492814	960220
APPLICATION INFO.:	US 92-970942	921103 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 91-725060, filed on 3 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 90-549434, filed on 6 Jul 1990, now abandoned	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Scheiner, Toni R.
 ASSISTANT EXAMINER: Chin, Christopher L.
 LEGAL REPRESENTATIVE: Fish & Richardson
 NUMBER OF CLAIMS: 32
 EXEMPLARY CLAIM: 23
 NUMBER OF DRAWINGS: 21 Drawing Figure(s); 16 Drawing Page(s)
 LINE COUNT: 2021

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A liquid that includes monocrystalline superparamagnetic particles and a method for preparing this liquid. Also featured are a method of decreasing the NMR relaxation times of water protons in contact with biological tissue using this liquid and an in vitro method for obtaining information from biological tissue or components thereof using this liquid.

L13 ANSWER 34 OF 39 USPATFULL
 ACCESSION NUMBER: 96:3496 USPATFULL
 TITLE: Detection and therapy of lesions with biotin/avidin polymer conjugates
 INVENTOR(S): Griffiths, Gary L., Morristown, NJ, United States
 PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5482698	960109
APPLICATION INFO.:	US 93-51144	930422 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Wu, Shean	
ASSISTANT EXAMINER:	Chapman, Lara E.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1738	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of detecting and/or treating lesions in a patient are provided. The methods are an improvement over known methods comprising the steps of (a) parenterally injecting a subject with a targeting composition comprised of a biotin-protein conjugate or an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced or associated with the targeted lesion, and allowing the protein conjugate to preferentially accrete at the targeted lesion; (b) then parenterally injecting a clearing composition comprised of (i) avidin, when the targeting composition is a biotin-protein conjugate, or (ii) biotin, when the targeting composition is an avidin-protein conjugate, and allowing the clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion; and (c) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin and detection or therapeutic agent when the clearing composition is biotin, or (ii) biotin and detection or therapeutic agent when the clearing agent is avidin, and allowing the composition to accrete at the targeted lesion. The improvement is having at least one of the compositions of step (a) or (b) further comprise a polymer to which multiple moieties of avidin or biotin can conjugate, thereby providing an increased number of binding sites to which a subsequently administered composition can bind thereby amplifying the amount of detection or therapeutic agent at the targeted site.

L13 ANSWER 33 OF 39 USPATFULL
 ACCESSION NUMBER: 96:8778 USPATFULL
 TITLE: Gas-filled polymeric microbubbles for ultrasound imaging
 INVENTOR(S): Cohen, Smadar, Petach-Tickva, Israel
 ANDRIANOV, Alexander K., Belmont, MA, United States
 Wheatley, Margaret, Media, PA, United States
 Allcock, Harry R., State College, PA, United States
 Langer, Robert S., Newton, MA, United States
 PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
 The Penn State Research Foundation, University Park, PA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5487390	960130
APPLICATION INFO.:	US 94-182216	940114 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 92-880248, filed on 8 May 1992, now patented, Pat. No. US 5308701 which is a division of Ser. No. US 90-593684, filed on 5 Oct 1990, now patented, Pat. No. US 5149543	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Kulkosky, Peter F.
 LEGAL REPRESENTATIVE: Arnall Golden & Gregory
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1205

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions, methods for preparing and methods of using air-filled polymeric microcapsules for ultrasound imaging are disclosed. Air-encapsulating microcapsules are formed by ionotropically gelling synthetic polyelectrolytes such as poly(carboxylatophenoxy)phosphazene, poly(acrylic acid), poly(methacrylic acid) and methacrylic acid copolymers (Eudragit's) by contact with multivalent ions such as calcium ions. In the preferred embodiment, the average size of the microcapsules is less than seven .mm.m so that they are suitable for injection intravenously. The polymeric microcapsules are stable to imaging and display high echogenicity, both in vitro and in vivo. Due to their in vivo stability their potential application is extended beyond vascular imaging to liver and renal diseases, fallopian tube diseases, detecting and characterizing tumor masses and tissues, and measuring peripheral blood velocity. The microcapsules can optionally be linked with ligands that minimize tissue adhesion or that target the microcapsules to specific regions.

L13 ANSWER 35 OF 39 USPATFULL
 ACCESSION NUMBER: 95:10485 USPATFULL
 TITLE: Methods of preparing gas-filled liposomes
 INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
 Fritz, Thomas A., Tucson, AZ, United States
 Matsunaga, Terry, Tucson, AZ, United States
 Ramaswami, VaradaRajan, Tucson, AZ, United States
 Yellowhair, David, Tucson, AZ, United States
 Wu, Guanli, Tucson, AZ, United States
 PATENT ASSIGNEE(S): InaR.sub.X Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5469854	951128
APPLICATION INFO.:	US 93-76239	930611 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 91-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 And Ser. No. US 91-716899, filed on 19 Jun 1991, now abandoned each which is a continuation-in-part of Ser. No. US 90-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499 which is a continuation-in-part of Ser. No. US 89-455707, filed on 22 Dec 1989, now abandoned	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Jaworski, Francis
 LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris
 NUMBER OF CLAIMS: 19
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
 LINE COUNT: 2090

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of and apparatus for preparing gas-filled liposomes are described. Gas-filled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.

L13 ANSWER 36 OF 39 USPATFULL
 ACCESSION NUMBER: 94:79758 USPATFULL
 TITLE: Phthalocyanine and tetrabenzotriazaporphyrin reagents
 INVENTOR(S): Renzoni, George E., Seattle, WA, United States
 Schindele, Deborah C., Seattle, WA, United States
 Theodore, Louis J., Seattle, WA, United States
 Leznoff, Clifford C., Ontario, Canada
 Pearson, Karen L., Woodinville, WA, United States
 Pepich, Barry V., Seattle, WA, United States
 PATENT ASSIGNEE(S): British Technology Group U.S.A. Inc., Gulph Mills, PA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5346670	940913
APPLICATION INFO.:	US 92-895601	920608 (7)
DISCLAIMER DATE:	20090804	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 89-398433, filed on 29 Aug 1989, now patented, Pat. No. US 5135717 And a continuation-in-part of Ser. No. US 89-366971, filed on 14 Jun 1989 which is a continuation-in-part of Ser. No. US 87-61937, filed on 12 Jun 1987, now abandoned And Ser. No. US 86-946475, filed on 24 Dec 1986, now patented, Pat. No. US 4803170, said Ser. No. US -398433 which is a continuation-in-part of Ser. No. US 88-241608, filed on 8 Sep 1988, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Yarbrough, Amelia Burgess	
LEGAL REPRESENTATIVE:	Christensen, O'Connor, Johnson & Kindness	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	2192	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Red-shifted, water-soluble, fluorescent, monomerically-tetherable derivatives having the formula: #STR1#	

wherein, M represents either H.sub.2 or is selected from among the following metals: aluminum, silicon, phosphorus, gallium, germanium, cadmium, scandium, magnesium, tin, and zinc. Each R.sub.1 is independently selected from --XYW, --YV, and --W. X represents either a carbon, or heteroatom selected from among oxygen, nitrogen, sulfur, phosphorus, silicon, and selenium; Y represents a linking group; and W represents a water solubilizing group. The substituent R.sub.2 is selected from among --A, --Y'A, --XA, and --XY'A, where A denotes a biological entity such as an antibody, antibody fragment, nucleotide, nucleic acid probe, antigen, oligonucleotide, deoxynucleotide, dideoxynucleotide, avidin, streptavidin or membrane probe, or R.sub.2 is a reactive or activatable group suitable for conjugating to a biological entity. Y' is a linking group that

L13 ANSWER 37 OF 39 USPATFULL
 ACCESSION NUMBER: 93:93543 USPATFULL
 TITLE: Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
 INVENTOR(S): Ranney, David F., 3539 Courtdale Dr., Dallas, TX, United States 75234

	NUMBER	DATE
PATENT INFORMATION:	US 5260050	931109
APPLICATION INFO.:	US 90-463692	900111 (7)
DISCLAIMER DATE:	20100525	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 88-252565, filed on 29 Sep 1988, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Hollrah, Glennon H.	
ASSISTANT EXAMINER:	Hollinden, Gary E.	
LEGAL REPRESENTATIVE:	Arnold, White Durkee	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	2936	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Improved compositions and methods for selective access to tumor regions (or other regions of abnormal endothelial properties). This capability provides powerful contrast-enhancement agents for nuclear magnetic resonance imaging. A polyatomic complex which includes intramolecular ferromagnetic coupling between metal atoms is associated with a polymer or microsphere carrier matrix which will bind to endothelial determinants. A solution containing this carrier complex is injected into a human (or other) body to be imaged. The carrier complex will preferentially extravasate at locations where the blood vessel walls have increased porosity or microvascular surface changes, and especially at tumor sites. Thus, the changes in relaxation time induced by the presence of the carrier complex will provide a high-gain marker for magnetic resonance imaging.	

Multiple superparamagnetic polyatomic complexes are described, including novel complexes which include acetate and glycinate bridging ligands with a polyatomic metal-atom-complex core.

L13 ANSWER 36 OF 39 USPATFULL (Continued)
 tethers the biological entity to the phthalocyanine or tetrabenzotriazaporphyrin macrocycle. Z is either a nitrogen atom or a carbon substituted with hydrogen, alkyl, aryl, or aralkyl groups. Z may also be attached to R.sub.2. Also disclosed are derivatives of the compounds of the above Formula in which 1-4 of the benzo ring(s) contain 1 or 2 N atoms. Methods of sequencing DNA and detecting analytes, including cells, using these derivatives are disclosed, as are kits for carrying out assays for the analytes and flow cytometry. Methods of detecting DNA using cationic compounds of the above Formula, wherein R.sub.2 = R.sub.1 and W = N.sub.4 O.sub.1 D.sub.1 D.sub.2 D.sub.3 are also disclosed. Further, compounds containing Tc, Gd, etc. as the metal in the above Formula may be used for imaging or therapy.

L13 ANSWER 38 OF 39 USPATFULL
 ACCESSION NUMBER: 93:41807 USPATFULL
 TITLE: Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
 INVENTOR(S): Ranney, David F., 3539 Courtdale Dr., Dallas, TX, United States 75234

	NUMBER	DATE
PATENT INFORMATION:	US 5213788	930525
APPLICATION INFO.:	US 91-680675	910404 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 90-463692, filed on 11 Jan 1990 which is a continuation-in-part of Ser. No. US 88-252565, filed on 29 Sep 1988, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Hollinden, Gary E.	
LEGAL REPRESENTATIVE:	Arnold, White & Durkee	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	3038	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Improved compositions and methods for selective access to tumor regions (or other regions of abnormal endothelial properties). This capability provides powerful contrast-enhancement agents for nuclear magnetic resonance imaging. A polyatomic complex which includes intramolecular ferromagnetic coupling between metal atoms is associated with a polymer or microsphere carrier matrix which will bind to endothelial determinants. A solution containing this carrier complex is injected into a human (or other) body to be imaged. The carrier complex will preferentially extravasate at locations where the blood vessel walls have increased porosity or microvascular surface changes, and especially at tumor sites. Thus, the changes in relaxation time induced by the presence of the carrier complex will provide a high-gain marker for magnetic resonance imaging.	

Multiple superparamagnetic polyatomic complexes are described, including novel complexes which include acetate and glycinate bridging ligands with a polyatomic metal-atom-complex core.

L13 ANSWER 39 OF 39 USPATFULL
 ACCESSION NUMBER: 92:63642 USPATFULL
 TITLE: Tetrabenztriazaporphyrin reagents and kits
 containing the same
 INVENTOR(S): Renzoni, George E., Seattle, WA, United States
 Schindele, Deborah C., Seattle, WA, United States
 Theodore, Louis J., Seattle, WA, United States
 Leznoff, Clifford C., North York, Canada
 Fearon, Karen L., Woodinville, WA, United States
 Pepich, Barry V., Seattle, WA, United States
 PATENT ASSIGNEE(S): British Technology Group USA Inc., Gulph Mills,
 PA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5135717	920804
APPLICATION INFO.:	US 89-398433	890829 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 88-241608, filed on 8 Sep 1988, now abandoned And a continuation-in-part of Ser. No. US 89-366971, filed on 14 Jun 1989 which is a continuation-in-part of Ser. No. US 87-3226, filed on 12 Nov 1987 which is a continuation-in-part of Ser. No. US 87-61937, filed on 12 Jun 1987, now abandoned And a continuation-in-part of Ser. No. US 86-946475, filed on 24 Dec 1986, now patented, Pat. No. US 4803170	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Hill, Jr., Robert J.	
LEGAL REPRESENTATIVE:	Christensen, O'Connor, Johnson & Kindness	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	2120	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Red-shifted, water-soluble, fluorescent, monomerically-tetherable derivatives having the formula: $\#STR1\#$ wherein, M represents either H.sub.2 or is selected from among the following metals: aluminum, silicon, phosphorus, gallium, germanium, cadmium, scandium, magnesium, tin, and zinc. Each R.sub.1 is independently selected from --XYW, --YW, and --W. X represents either a carbon, or heteroatom selected from among oxygen, nitrogen, sulfur, phosphorus, silicon, and selenium; Y represents a linking group; and W represents a water solubilizing group. The substituent R.sub.2 is selected from among --A, --Y'A, --XA, and --XY'A, where A denotes a biological entity such as an antibody, antibody fragment, nucleotide, nucleic acid probe, antigen, oligonucleotide, deoxynucleotide, dideoxynucleotide, avidin, streptavidin or membrane probe, or R.sub.2 is a reactive or activatable group suitable for conjugating to a biological entity. Y' is a linking group that tethers the biological entity to the phthalocyanine or tetrabenztriazaporphyrin macrocycle. Z is

L13 ANSWER 39 OF 39 USPATFULL (Continued)
 either a nitrogen atom or a carbon substituted with hydrogen, alkyl, aryl, or aralkyl groups. Z may also be attached to R.sub.2. Also disclosed are derivatives of the compounds of the above formula in which 1-4 of the benzo rings(s) contain 1 or 2 N atoms. Methods of sequencing DNA and detecting analytes, including cells, using these derivatives are disclosed, as are kits for carrying out assays for the analytes and flow cytometry. Methods of detecting DNA using cationic compounds of the above formula, wherein R.sub.2 = R.sub.1 and W = --N.sup.+ D.sub.1 D.sub.2 D.sub.3 are also disclosed. Further, compounds containing Tc, Gd, etc. as the metal in the above formula may be used for imaging or therapy.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

92.58

92.88

STN INTERNATIONAL LOGOFF AT 13:39:02 ON 03 FEB 1998


```
PLEASE ENTER HOST PORT ID:
INVALID PORT POOL ID ENTERED
PLEASE REENTER HOST PORT ID:x
LOGINID:dl28dlj
PASSWORD:
TERMINAL (ENTER 1, 2, 3, 4, OR ?):3
```

Welcome to MESSENGER (APS Text) at USPTO

The USPTO production files are current through:
FEB 03 1998 for U.S. Patent Text Data.
FEB 03 1998 for U.S. Current Classification data.
FEB 03 1998 for U.S. Patent Image Data.

* PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *

More U.S. patent data is now available on APS. The new
USOCR file contains patents issued in 1970, plus some
patents that were missing from the USPAT file. See the
Patents News Folder under the Public Folders in e-mail for
more information on using the new file. Thank you.

DISCLAIMER:

Neither the United States Government, nor any agency
thereof, nor any of their contractors, subcontractors or
employees make any warranty, expressed or implied,
including any warranty of marketability of fitness for a
particular purpose; nor assumes any legal liability or
responsibility for any party's use, or the results of
such, of the data.

Help Desk --> 703-305-9000

The Help Desk is staffed for APS support 7 days/week.
Monday through Friday: 6:30am - 9:00pm
Saturday, Sunday, Holidays: 8:30am - 5:00 pm

The Help Desk staff at this number will handle all APS
related questions.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>><<<<<<<<<<<<<<<<<<

The APS is available:
6:30am - 9:00pm Monday through Friday
7:30am - 5:00pm Saturday, Sunday, Holidays

APS is unavailable Thanksgiving Day, Christmas Day,
and New Year's Day.

```

* * * * *
*           W E L C O M E   T O   T H E           *
*           U . S .   P A T E N T   T E X T   F I L E           *
* * * * *

```

```

=> s 424/1.11,1.65,1.73,9.1,9.3,9.34,9.5,9.6/ccls
    88 424/1.11/CCLS
    226 424/1.65/CCLS
    73 424/1.73/CCLS
    132 424/9.1/CCLS
    79 424/9.3/CCLS
    106 424/9.34/CCLS
    70 424/9.5/CCLS
    72 424/9.6/CCLS
L1    720 424/1.11,1.65,1.73,9.1,9.3,9.34,9.5,9.6/CCLS
      ((424/1.11 OR 424/1.65 OR 424/1.73 OR 424/9.1 OR 424/9.3
OR
      424/9.34 OR 424/9.5 OR 424/9.6)/CCLS)

=> s 530/300,324,325,326,327,328,329,330/ccls
    634 530/300/CCLS
    1242 530/324/CCLS
    357 530/325/CCLS
    763 530/326/CCLS
    675 530/327/CCLS
    856 530/328/CCLS
    666 530/329/CCLS
    899 530/330/CCLS
L2    3391 530/300,324,325,326,327,328,329,330/CCLS
      ((530/300 OR 530/324 OR 530/325 OR 530/326 OR 530/327 OR
530
      /328 OR 530/329 OR 530/330)/CCLS)

=> s 534/10,11,12,13,14,15,16/ccls
    553 534/10/CCLS
    405 534/11/CCLS
    172 534/12/CCLS
    297 534/13/CCLS
    503 534/14/CCLS
    609 534/15/CCLS
    475 534/16/CCLS
L3    1664 534/10,11,12,13,14,15,16/CCLS
      ((534/10 OR 534/11 OR 534/12 OR 534/13 OR 534/14 OR 534/1
5 O
      R 534/16)/CCLS)

=> s 536/22.1,25.6,26.1,27.1/ccls
    407 536/22.1/CCLS
    55 536/25.6/CCLS
    54 536/26.1/CCLS
    68 536/27.1/CCLS
L4    551 536/22.1,25.6,26.1,27.1/CCLS
      ((536/22.1 OR 536/25.6 OR 536/26.1 OR 536/27.1)/CCLS)

=> s 11 or 12 or 13 or 14
L5    6089 L1 OR L2 OR L3 OR L4

=> s 15 and polymer?

```

```

        314940 POLYMER?
L6      2434 L5 AND POLYMER?

=> s 16 and (contrast? or imag?)
        256619 CONTRAST?
        303742 IMAG?
L7      1047 L6 AND (CONTRAST? OR IMAG?)

=> s 17 and (chelate? or ligand?)
        26473 CHELAT?
        21658 LIGAND?
L8      587 L7 AND (CHELAT? OR LIGAND?)

=> s 18 and (cell?)
        360863 CELL?
L9      510 L8 AND (CELL?)

=> s 19 and (polyamine? or spermidine? or polylysine?)
        23418 POLYAMINE?
        1149 SPERMIDINE?
        1310 POLYLYSINE?
L10     116 L9 AND (POLYAMINE? OR SPERMIDINE? OR POLYLYSINE?)

=> s 110 and (polynucleo? or dna or nucleic or oligonucleo? or
deoxyribonucleic)
        4842 POLYNUCLEO?
        22283 DNA
        15234 NUCLEIC
        8769 OLIGONUCLEO?
        1753 DEOXYRIBONUCLEIC
L11     63 L10 AND (POLYNUCLEO? OR DNA OR NUCLEIC OR OLIGONUCLEO? OR D
EOX      YRIBONUCLEIC)

=> s 111 and target?
        108082 TARGET?
L12     57 L11 AND TARGET?

=> s 112 and deliver?
        295667 DELIVER?
L13     38 L12 AND DELIVER?

=> s 113 and uptake?
        18911 UPTAKE?
L14     26 L13 AND UPTAKE?

=> d bib ab 1-

```

```

US PAT NO:      5,714,166 :IMAGE AVAILABLE:      L14: 1 of 26
DATE ISSUED:    Feb. 3, 1998
TITLE:          Bioactive and/or targeted dendrimer conjugates
INVENTOR:       Donald A. Tomalia, Midland, MI
                  James R. Baker, Ann Arbor, MI
                  Roberta C. Cheng, Midland, MI
                  Anna U. Bielinska, Ypsilanti, MI
                  Michael J. Fazio, Midland, MI
                  David M. Hedstrand, Midland, MI

```

Jennifer A. Johnson, Livonia, MI
Donald A. Kaplan, deceased, late of Marina del Rey, CA, by
Margorie Kaplan, executor
Scott L. Klakamp, Russell, PA
William J. Kruper, Jr., Sanford, MI
Jolanta Kukowska-Latallo, Ann Arbor, MI
Bartley D. Maxon, St. Louis, MI
Lars T. Piehler, Midland, MI
Ian A. Tomlinson, Midland, MI
Larry R. Wilson, Beaverton, MI
Rui Yin, Mt. Pleasant, MI
Herbert M. Brothers, II, Midland, MI
ASSIGNEE: The Dow Chemical Company, Midland, MI (U.S. corp.)
Dendritech Incorporated, Midland, MI (U.S. corp.)
The Regents of the University of Michigan, Ann Arbor, MI
(U.S. corp.)
APPL-NO: 08/400,203
DATE FILED: Mar. 7, 1995
ART-UNIT: 152
PRIM-EXMR: Gollamudi S. Kishore
LEGAL-REP: Karen L. Kimble

US PAT NO: 5,714,166 :IMAGE AVAILABLE: L14: 1 of 26

ABSTRACT:

Dendritic **polymer** conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a **target** director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic **polymers** are dense star **polymers**, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.

US PAT NO: 5,710,001 :IMAGE AVAILABLE: L14: 2 of 26
DATE ISSUED: Jan. 20, 1998
TITLE: 17q-linked breast and ovarian cancer susceptibility gene
INVENTOR: Mark H. Skolnick, Salt Lake City, UT
David E. Goldgar, Salt Lake City, UT
Yoshio Miki, Salt Lake City, UT
Jeff Swenson, Salt Lake City, UT
Alexander Kamb, Salt Lake City, UT
Keith D. Harshman, Salt Lake City, UT
Donna M. Shattuck-Eidens, Salt Lake City, UT
Sean V. Tavtigian, Salt Lake City, UT
Roger W. Wiseman, Durham, NC
P. Andrew Futreal, Durham, NC
ASSIGNEE: Myriad Genetics, Inc., Salt Lake City, UT (U.S. corp.)
University of Utah Research Foundation, Salt Lake City, UT
(U.S. corp.)
The United States of America as represented by the
Secretary of Health and Human Services, Technology
Transfer Office, Washington, DC (U.S. govt.)
APPL-NO: 08/487,002
DATE FILED: Jun. 7, 1995
ART-UNIT: 187

PRIM-EXMR: W. Gary Jones
ASST-EXMR: Dianne Rees
LEGAL-REP: Venable, Baetjer, Howard & Civiletti, LLP

US PAT NO: 5,710,001 :IMAGE AVAILABLE: L14: 2 of 26

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

US PAT NO: 5,705,333 :IMAGE AVAILABLE: L14: 3 of 26
DATE ISSUED: Jan. 6, 1998
TITLE: Peptide-based **nucleic** acid mimics (PENAMS)
INVENTOR: Vibhakar J. Shah, San Francisco, CA
George L. Kenyon, San Francisco, CA
Irwin D. Kuntz, Greenbrae, CA
ASSIGNEE: The Regents of The University of California, Oakland, CA
(U.S. corp.)
APPL-NO: 08/286,875
DATE FILED: Aug. 5, 1994
ART-UNIT: 189
PRIM-EXMR: Charles C.P. Rories
LEGAL-REP: Morrison & Foerster

US PAT NO: 5,705,333 :IMAGE AVAILABLE: L14: 3 of 26

ABSTRACT:

The present invention provides novel **nucleic** acid mimics (termed "PENAMs") comprising a peptidic backbone and nucleotidic sidechains; the sidechains being oriented in such a way that the PENAM is homomorphous to **target nucleic** acids with which it can effectively hydrogen bond. Homomorphism is achieved by the incorporation of unusual stereochemical centers, including D-chiral centers and quasi-chiral centers, into the peptidic backbone. The PENAMs are useful for **targeting nucleic** acid sequences in order to modulate their activity in an "antisense" manner. **Targeting** can also be used to detect, isolate or modify **target nucleic** acids.

US PAT NO: 5,703,045 :IMAGE AVAILABLE: L14: 4 of 26
DATE ISSUED: Dec. 30, 1997

TITLE: Treating disorders by application of insulin-like growth factors and analogs
INVENTOR: Michael E. Lewis, West Chester, PA
James C. Kauer, Kennet Square, PA
Kevin R. Smith, Parkesburg, PA
Kathleen V. Callison, Merchantville, NJ
Frank Baldino, Landenberg, PA
Nicola Neff, Wallingford, PA
Mohamed Iqbal, Malvern, PA
ASSIGNEE: Cephalon, Inc., West Chester, PA (U.S. corp.)
APPL-NO: 08/462,018
DATE FILED: Jun. 5, 1995
ART-UNIT: 181
PRIM-EXMR: Cecilia J. Tsang
ASST-EXMR: P. Lynn Touzeau
LEGAL-REP: Fish & Richardson P.C.

US PAT NO: 5,703,045 :IMAGE AVAILABLE: L14: 4 of 26

ABSTRACT:

A method of enhancing the survival of neuronal **cells** in a mammal, the **cells** being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.

US PAT NO: 5,698,405 :IMAGE AVAILABLE: L14: 5 of 26
DATE ISSUED: Dec. 16, 1997
TITLE: Method of reducing immunogenicity
INVENTOR: David M. Goldenberg, Short Hills, NJ
ASSIGNEE: Immunomedics, Inc., Morris Plains, NJ (U.S. corp.)
APPL-NO: 08/456,393
DATE FILED: Jun. 1, 1995
ART-UNIT: 187
PRIM-EXMR: Carol A. Spiegel
LEGAL-REP: Foley & Lardner

US PAT NO: 5,698,405 :IMAGE AVAILABLE: L14: 5 of 26

ABSTRACT:

The immunogenicity of avidin, a therapeutic agent moiety of a conjugate, or a **targeting** composition is reduced by coupling the immunogenic agent with a carbohydrate **polymer** or polyol groups, such as polysaccharides (e.g. dextran), polyethylene glycol and the like.

US PAT NO: 5,698,178 :IMAGE AVAILABLE: L14: 6 of 26
DATE ISSUED: Dec. 16, 1997
TITLE: Polyspecific immunoconjugates and antibody composites for **targeting** the multidrug resistant phenotype
INVENTOR: David M. Goldenberg, Mendham, NJ
ASSIGNEE: Immunomedics, Inc., Morris Plains, NJ (U.S. corp.)
APPL-NO: 08/629,387
DATE FILED: Apr. 8, 1996
ART-UNIT: 186
PRIM-EXMR: Christina Y. Chan
ASST-EXMR: Emma Cech

LEGAL-REP: Foley & Lardner

US PAT NO: 5,698,178 :IMAGE AVAILABLE: L14: 6 of 26

ABSTRACT:

Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor **cells**, multidrug resistant HIV-infected **cells** or multidrug resistant infectious agents.

US PAT NO: 5,693,773 :IMAGE AVAILABLE: L14: 7 of 26

DATE ISSUED: Dec. 2, 1997

TITLE: Triplex-forming antisense **oligonucleotides** having
abasic linkers **targeting nucleic acids**
comprising mixed sequences of purines and pyrimidines

INVENTOR: Ekambar Kandimalla, Worcester, MA

Sudhir Agrawal, Shrewsbury, MA

ASSIGNEE: Hybridon Incorporated, Cambridge, MA (U.S. corp.)

APPL-NO: 08/473,096

DATE FILED: Jun. 7, 1995

ART-UNIT: 187

PRIM-EXMR: W. Gary Jones

ASST-EXMR: Dianne Rees

LEGAL-REP: McDonnell Boehnen Hulbert & Berghoff

US PAT NO: 5,693,773 :IMAGE AVAILABLE: L14: 7 of 26

ABSTRACT:

The present invention provides a novel class of antisense **oligonucleotides** capable of hybridizing to and inhibiting expression of **nucleic acids** having mixed purine/pyrimidine sequences by triplex formation. The foldback triplex-forming **oligonucleotides** (FTFOs) of the invention are comprised of three regions, a duplex-forming region, which is sufficiently complementary to a region of the **target nucleic acid** to hybridizes to it under the conditions of interest, a triplex-forming region, which is an inverted repeat of the duplex-forming region and folds back upon the duplex formed between the duplex-forming region and the **target nucleic acid** to form a triplex, and a linker region, which connects the duplex-forming region and the triplex-forming region and allows formation of the triplex. A novel aspect of the FTFOs of the present invention is that from one to five abasic linkers substitute for nucleotides in the triplex-forming region and are positioned to match up with pyrimidine residues of the **target** when a triplex is formed. This allows the FTFOs of the present invention to **target nucleic acid** sequences having mixed purine/pyrimidine sequences. FTFOs according to the invention are useful for both in vitro and in vivo modulation of gene expression.

US PAT NO: 5,677,427 :IMAGE AVAILABLE: L14: 8 of 26

DATE ISSUED: Oct. 14, 1997

TITLE: Chimeric antibody for detection and therapy of infectious
and inflammatory lesions

INVENTOR: David M. Goldenberg, Short Hills, NJ

ASSIGNEE: Hans J. Hansen, Mystic Island, NJ
Immunomedics, Inc., Morris Plains, NJ (U.S. corp.)
APPL-NO: 08/457,138
DATE FILED: Jun. 1, 1995
ART-UNIT: 186
PRIM-EXMR: Lila Feisee
ASST-EXMR: Julie E. Reeves
LEGAL-REP: Foley & Lardner

US PAT NO: 5,677,427 :IMAGE AVAILABLE: L14: 8 of 26

ABSTRACT:

A chimeric antibody-agent conjugate for **targeting** foci of leukocyte accretion comprises a recombinant chimera having an antigen-binding hypervariable region which binds specifically to granulocytes, and a constant region of a human immunoglobulin having an Fc portion with high affinity for receptors on human mononuclear lymphoid **cells**, said chimera being conjugated to at least one diagnostic agent or therapeutic agent.

A method for **targeting** an **imaging** or therapy agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for **targeting** of the above chimeric anti-leukocyte conjugate.

US PAT NO: 5,674,977 :IMAGE AVAILABLE: L14: 9 of 26
DATE ISSUED: Oct. 7, 1997
TITLE: Branched synthetic peptide conjugate
INVENTOR: Jean Gariepy, Toronto, Canada
ASSIGNEE: The Ontario Cancer Institute, Toronto, Canada (foreign corp.)
APPL-NO: 08/257,307
DATE FILED: Jun. 9, 1994
ART-UNIT: 181
PRIM-EXMR: Jeffrey E. Russel
LEGAL-REP: Ridout & Maybee

US PAT NO: 5,674,977 :IMAGE AVAILABLE: L14: 9 of 26

ABSTRACT:

The invention is a branched synthetic peptide conjugate which can be designed to bind to a **target cell** surface receptor, to penetrate into **target cells**, and to **deliver** a diagnostic probe or cytotoxic functionality to a desired site of action. The invention provides a relatively small molecule of flexible design having a branched structure for systematically incorporating a desired number of cytotoxic functions, peptide-based localization signals or diagnostic probes. The invention addresses problems associated with protein-based therapeutic or diagnostic agents.

US PAT NO: 5,670,617 :IMAGE AVAILABLE: L14: 10 of 26
DATE ISSUED: Sep. 23, 1997
TITLE: **Nucleic acid** conjugates of tat-derived transport polypeptides
INVENTOR: Alan Frankel, 21 Marinero Cir. #206, Tiburon, CA 94920
Carl Pabo, 18 Weldon Rd., Newton, MA 02158
James G. Barsoum, 9 Marlboro Rd., Lexington, MA 02173

Stephen E. Fawell, One Black Horse Ter., Winchester, MA
01890
R. Blake Pepinsky, 30 Falmouth Rd., Arlington, MA 02174
APPL-NO: 08/450,246
DATE FILED: May 25, 1995
ART-UNIT: 189
PRIM-EXMR: George C. Elliot
ASST-EXMR: Thomas G. Larson
LEGAL-REP: James F. Haley, Jr., Madge R. Kanter

US PAT NO: 5,670,617 :IMAGE AVAILABLE: L14: 10 of 26

ABSTRACT:

This invention relates to **delivery** of biologically active cargo molecules, such as polypeptides and **nucleic** acids, into the cytoplasm and nuclei of **cells** in vitro and in vivo. Intracellular **delivery** of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation. The reduced size of the preferred transport polypeptides of this invention also minimizes interference with the biological activity of the cargo molecule.

US PAT NO: 5,641,748 :IMAGE AVAILABLE: L14: 11 of 26
DATE ISSUED: Jun. 24, 1997
TITLE: Caip-like gene family
INVENTOR: Yen-Ming Hsu, Lexington, MA
ASSIGNEE: Biogen, Inc., Cambridge, MA (U.S. corp.)
APPL-NO: 08/475,894
DATE FILED: Jun. 7, 1995
ART-UNIT: 184
PRIM-EXMR: Robert A. Wax
ASST-EXMR: Lisa J. Hobbs
LEGAL-REP: LouisLahive & Cockfield Myers

US PAT NO: 5,641,748 :IMAGE AVAILABLE: L14: 11 of 26

ABSTRACT:

A substantially pure preparation of a polypeptide, the sequence of which comprises the sequence of a CAIP polypeptide.

US PAT NO: 5,639,441 :IMAGE AVAILABLE: L14: 12 of 26
DATE ISSUED: Jun. 17, 1997
TITLE: Methods for fine particle formation
INVENTOR: Robert E. Sievers, Boulder, CO
Uwe Karst, Muenster, Federal Republic of Germany
ASSIGNEE: Board of Regents of University of Colorado, Boulder, CO
(U.S. corp.)
APPL-NO: 08/224,764

DATE FILED: Apr. 8, 1994
ART-UNIT: 128
PRIM-EXMR: Richard D. Lovering
LEGAL-REP: Greenlee, Winner and Sullivan, P.C.

US PAT NO: 5,639,441 :IMAGE AVAILABLE: L14: 12 of 26

ABSTRACT:

Methods and apparatuses are provided for forming fine particles of a desired substance comprising dissolving said substance in a fluid such as water to form a solution and mixing the solution with a second fluid such as supercritical carbon dioxide which becomes a gas upon rapid pressure release, and with which the first fluid is at least partially immiscible, and releasing the pressure to form an air-borne dispersion or aerosol comprising particles having an average diameter between about 0.1 and about 6.5 .mu.m.

US PAT NO: 5,637,288 :IMAGE AVAILABLE: L14: 13 of 26
DATE ISSUED: Jun. 10, 1997
TITLE: Chimeric antibody for detection and therapy of infectious
and inflammatory lesions
INVENTOR: David M. Goldenberg, Short Hills, NJ
Hans J. Hansen, Mystic Island, NJ
ASSIGNEE: Immunomedics, Inc., Morris Plains, NJ (U.S. corp.)
APPL-NO: 08/457,134
DATE FILED: Jun. 1, 1995
ART-UNIT: 186
PRIM-EXMR: Lila Feisee
ASST-EXMR: Julie E. Reeves
LEGAL-REP: Foley & Lardner

US PAT NO: 5,637,288 :IMAGE AVAILABLE: L14: 13 of 26

ABSTRACT:

A chimeric antibody-agent conjugate for **targeting** foci of leukocyte accretion comprises a recombinant chimera having an antigen-binding hypervariable region which binds specifically to granulocytes, and a constant region of a human immunoglobulin having an Fc portion with high affinity for receptors on human mononuclear lymphoid **cells**, said chimera being conjugated to at least one diagnostic agent or therapeutic agent.

A method for **targeting** an **imaging** or therapy agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for **targeting** of the above chimeric anti-leukocyte conjugate.

US PAT NO: 5,607,924 :IMAGE AVAILABLE: L14: 14 of 26
DATE ISSUED: Mar. 4, 1997
TITLE: **DNA** photocleavage using texaphyrins
INVENTOR: Darren Magda, Cupertino, CA
Jonathan L. Sessler, Austin, TX
Brent L. Iverson, Austin, TX
Petra I. Sansom, Austin, TX
Meredith Wright, San Jose, CA
ASSIGNEE: Pharmacyclics, Inc., Sunnyvale, CA (U.S. corp.)
Board of Trustees, Univ. of TX Sys., Austin, TX (U.S.)

corp.)
APPL-NO: 08/469,177
DATE FILED: Jun. 6, 1995
ART-UNIT: 129
PRIM-EXMR: Richard L. Raymond
LEGAL-REP: Jacqueline S. Larson

US PAT NO: 5,607,924 :IMAGE AVAILABLE: L14: 14 of 26

ABSTRACT:

Methods of cleavage of a **polymer** of **deoxyribonucleic** acid using photosensitive texaphyrins are disclosed. A preferred method of use is the site-specific cleavage of a **polymer** of **deoxyribonucleic** acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an **oligonucleotide**.

US PAT NO: 5,607,659 :IMAGE AVAILABLE: L14: 15 of 26
DATE ISSUED: Mar. 4, 1997
TITLE: Directed biodistribution of radiolabelled biotin using carbohydrate **polymers**
INVENTOR: Linda M. Gustavson, Seattle, WA
Alan R. Fritzberg, Edmonds, WA
ASSIGNEE: NeoRx Corporation, Seattle, WA (U.S. corp.)
APPL-NO: 08/482,788
DATE FILED: Jun. 7, 1995
ART-UNIT: 121
PRIM-EXMR: Gary E. Hollinden
ASST-EXMR: Lara E. Chapman
LEGAL-REP: Burns, Doane, Swecker & Mathis, LLP

US PAT NO: 5,607,659 :IMAGE AVAILABLE: L14: 15 of 26

ABSTRACT:

The present invention provides methods for directing the biodistribution of molecules that are not generally specifically excreted via the renal pathway to renal excretion. The methods employ conjugates or complexes containing a directed biodistribution molecule (DBM) and one or more bound molecules, wherein the biodistribution of the conjugate or complex is directed to renal excretion in vivo by the DBM component thereof.

US PAT NO: 5,599,796 :IMAGE AVAILABLE: L14: 16 of 26
DATE ISSUED: Feb. 4, 1997
TITLE: Treatment of urogenital cancer with boron neutron capture therapy
INVENTOR: Raymond F. Schinazi, Decatur, GA
Thomas E. Keane, Dunwoody, GA
Dennis C. Liotta, McDonough, GA
ASSIGNEE: Emory University, Atlanta, GA (U.S. corp.)
APPL-NO: 08/334,759
DATE FILED: Nov. 4, 1994
ART-UNIT: 121
PRIM-EXMR: James O. Wilson
LEGAL-REP: Sherry M. Knowles

US PAT NO: 5,599,796 :IMAGE AVAILABLE: L14: 16 of 26

ABSTRACT:

Methods and compositions for treating urogenital tumors, and particular, cancer of the prostate, bladder, and kidney, with BNCT, are disclosed. Any boron-containing compound that is sufficiently lipophilic to pass through the appropriate urogenital membranes in a quantity high enough to achieve therapy on irradiation with low-energy neutrons can be used. Carboranyl-containing nucleosides and **oligonucleotides** are particularly suited for use in BNCT of urogenital tumors. Preferred compounds include 5-carboranyl-2'-deoxyuridine (CDU) and 5-o-carboranyl-1-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)uracil (CFAU). Nucleosides and **oligonucleotides** bearing an -O-:(carboran-1-yl)alkyl:phosphate, S-:(carboran-1-yl)alkyl:phosphorothioate, or Se-:(carboran-1-yl)alkyl:phosphoroselenoate in place of the (carboran-1-yl)phosphonate moiety can be used. **Oligonucleotides** of specific gene sequences that include one or more 3',5'-linking-(carboran-1-yl)phosphonate moieties can also be used in antisense therapy in the selective modification of gene expression. Compounds can be used in urogenital BNCT therapy that contain boron clusters as a means to enhance lipophilicity wherein the boron is not enriched in .sup.10 B, but instead, in the .sup.11 B isotope. The therapy is accomplished by administering the boron-containing compound by any appropriate route, including by intravenous injection, oral **delivery** or by catheter or other direct means, in such a manner that the compound accumulates in the **target** tumor. After desired accumulation of the compound in the tumor, the site is irradiated with an effective amount of low energy neutrons.

US PAT NO: 5,550,034 :IMAGE AVAILABLE: L14: 17 of 26
DATE ISSUED: Aug. 27, 1996
TITLE: Apolipoprotein B mRNA editing protein compositions and methods
INVENTOR: BaBie Teng, Gaithersburg, MD
Nicholas O. Davidson, Olympia Fields, IL
Charles F. Burant, Chicago Heights, IL
ASSIGNEE: Arch Development Corp., Chicago, IL (U.S. corp.)
Northwestern University, Evanston, IL (U.S. corp.)
APPL-NO: 08/015,203
DATE FILED: Feb. 9, 1993
ART-UNIT: 184
PRIM-EXMR: Robert A. Wax
ASST-EXMR: Hyosuk Kim
LEGAL-REP: Arnold White & Durkee

US PAT NO: 5,550,034 :IMAGE AVAILABLE: L14: 17 of 26

ABSTRACT:

The present invention provides a protein that edits apo B RNA. A **polynucleotide** that comprises a **DNA** sequence that encodes an apo B RNA editing protein and an expression vector comprising such a **polynucleotide** are also provided. Processes for producing an apo B RNA editing protein, editing apo B RNA and altering apo B protein production are also provided.

US PAT NO: 5,549,883 :IMAGE AVAILABLE: L14: 18 of 26
DATE ISSUED: Aug. 27, 1996

TITLE: Chemically defined **polymeric** carriers for release of
covalently linked agents
INVENTOR: Ananthachari Srinivasan, St. Charles, MO
Vivekananda M. Vrudhula, Edmonds, WA
Diana I. Brixner, Lynnwood, WA
ASSIGNEE: NeoRx Corporation, Seattle, WA (U.S. corp.)
APPL-NO: 08/071,357
DATE FILED: Jun. 3, 1993
ART-UNIT: 128
PRIM-EXMR: Shean Wu
ASST-EXMR: Lara E. Chapman
LEGAL-REP: Burns, Doane, Swecker & Mathis

US PAT NO: 5,549,883 :IMAGE AVAILABLE: L14: 18 of 26

ABSTRACT:

A chemically defined **polymeric** carrier comprising a series of .alpha.-amino acids in any combination containing side chains to which diagnostic/therapeutic and **chelating** agents can be covalently joined through cleavable linkers either directly or covalently joined through cleavable linkers after chemical modification of the side chains. Hydrazone, disulfide, and ester linkages in any combination can be present in the **polymeric** carrier between the side chains of the .alpha.-amino acids and the agents. The presence of a particular covalent linkage between the side chain and the agent in the carrier is determined by the functional group present in the side chain of the .alpha.-amino acid and the functional group present in the agent. The .alpha.-amino acids with side chains to which agents do not covalently join can function as spacers to minimize interaction between bulky molecules attached to the **polymeric** carrier. In addition, those .alpha.-amino acids with charged or hydrophilic side chains to which agents do not covalently join can provide increased solubility to the **polymeric** carrier.

US PAT NO: 5,541,287 :IMAGE AVAILABLE: L14: 19 of 26
DATE ISSUED: Jul. 30, 1996
TITLE: Pretargeting methods and compounds
INVENTOR: Eric K. Yau, Kirkland, WA
Louis J. Theodore, Lynnwood, WA
Linda M. Gustavson, Seattle, WA
ASSIGNEE: NeoRx Corporation, Seattle, WA (U.S. corp.)
APPL-NO: 08/345,811
DATE FILED: Nov. 22, 1994
ART-UNIT: 181
PRIM-EXMR: Christina Y. Chan
ASST-EXMR: Benet Prickril
LEGAL-REP: Burns, Doane, Swecker & Mathis, L.L.P.

US PAT NO: 5,541,287 :IMAGE AVAILABLE: L14: 19 of 26

ABSTRACT:

Methods, compounds, compositions and kits that relate to pretargeted **delivery** of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.

US PAT NO: 5,527,524 :IMAGE AVAILABLE: L14: 20 of 26
DATE ISSUED: Jun. 18, 1996
TITLE: Dense star **polymer** conjugates
INVENTOR: Donald A. Tomalia, Midland, MI
Larry R. Wilson, Beaverton, MI
David M. Hedstrand, Midland, MI
Ian A. Tomlinson, Midland, MI
Michael J. Fazio, Midland, MI
William J. Kruper, Jr., Sanford, MI
Donald A. Kaplan, Cincinnati, OH
Roberta C. Cheng, Midland, MI
David S. Edwards, Burlington, MA
Chu W. Jung, Arlington, MA
ASSIGNEE: The Dow Chemical Company, Midland, MI (U.S. corp.)
APPL-NO: 08/043,198
DATE FILED: Apr. 5, 1993
ART-UNIT: 152
PRIM-EXMR: Thurman K. Page
LEGAL-REP: Karen L. Kimble

US PAT NO: 5,527,524 :IMAGE AVAILABLE: L14: 20 of 26

ABSTRACT:

Dense star **polymer** conjugates which are composed of at least one dendrimer in association with at least one unit of a carried agricultural, pharmaceutical, or other material have been prepared. These conjugates have particularly advantageous properties due to the unique characteristics of the dendrimer.

US PAT NO: 5,482,698 :IMAGE AVAILABLE: L14: 21 of 26
DATE ISSUED: Jan. 9, 1996
TITLE: Detection and therapy of lesions with biotin/avidin **polymer** conjugates
INVENTOR: Gary L. Griffiths, Morristown, NJ
ASSIGNEE: Immunomedics, Inc., Morris Plains, NJ (U.S. corp.)
APPL-NO: 08/051,144
DATE FILED: Apr. 22, 1993
ART-UNIT: 128
PRIM-EXMR: Shean Wu
ASST-EXMR: Lara E. Chapman
LEGAL-REP: Foley & Lardner

US PAT NO: 5,482,698 :IMAGE AVAILABLE: L14: 21 of 26

ABSTRACT:

Methods of detecting and/or treating lesions in a patient are provided. The methods are an improvement over known methods comprising the steps of (a) parenterally injecting a subject with a **targeting** composition comprised of a biotin-protein conjugate or an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced or associated with the **targeted** lesion, and allowing the protein conjugate to preferentially accrete at the **targeted** lesion; (b) then parenterally injecting a clearing composition comprised of (i) avidin, when the **targeting** composition is a biotin-protein conjugate, or (ii) biotin, when the **targeting** composition is a avidin-protein conjugate, and allowing the clearing composition to substantially clear the

targeting composition from non-**targeted** sites and to bind to the **targeting** composition accreted at the **targeted** lesion; and (c) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin and detection or therapeutic agent when the clearing composition is biotin, or (ii) biotin and detection or therapeutic agent when the clearing agent is avidin, and allowing the composition to accrete at the **targeted** lesion. The improvement is having at least one of the compositions of step (a) or (b) further comprise a **polymer** to which multiple moieties of avidin or biotin can conjugate, thereby providing an increased number of binding sites to which a subsequently administrated composition can bind thereby amplifying the amount of detection or therapeutic agent at the **targeted** site.

US PAT NO: 5,434,058 :IMAGE AVAILABLE: L14: 22 of 26
DATE ISSUED: Jul. 18, 1995
TITLE: Apolipoprotein B mRNA editing protein compositions and methods
INVENTOR: Nicholas O. Davidson, Olympia Fields, IL
ASSIGNEE: Arch Development Corporation, Chicago, IL (U.S. corp.)
APPL-NO: 08/158,682
DATE FILED: Nov. 24, 1993
ART-UNIT: 184
PRIM-EXMR: Robert A. Wax
ASST-EXMR: Hyosuk Kim
LEGAL-REP: Arnold, White & Durkee

US PAT NO: 5,434,058 :IMAGE AVAILABLE: L14: 22 of 26

ABSTRACT:

The present invention provides a protein that edits apo B RNA. A **polynucleotide** that comprises a **DNA** sequence that encodes an apo B RNA editing protein and an expression vector comprising such a **polynucleotide** are also provided. Processes for producing an apo B RNA editing protein, editing apo B RNA and altering apo B protein production are also provided.

US PAT NO: 5,350,671 :IMAGE AVAILABLE: L14: 23 of 26
DATE ISSUED: Sep. 27, 1994
TITLE: HCV immunoassays employing C domain antigens
INVENTOR: Michael Houghton, Danville, CA
Qui-Lim Choo, El Cerrito, CA
George Kuo, San Francisco, CA
ASSIGNEE: Chiron Corporation, Emeryville, CA (U.S. corp.)
APPL-NO: 08/103,961
DATE FILED: Aug. 9, 1993
ART-UNIT: 187
PRIM-EXMR: Margaret Parr
ASST-EXMR: Bradley Lounsbury Sisson
LEGAL-REP: Gladys H. Monroy, Thomas E. Ciotti, Robert P. Blackburn

US PAT NO: 5,350,671 :IMAGE AVAILABLE: L14: 23 of 26

ABSTRACT:

Immunoassays for the detection of antibodies to HCV are provided which employ "C" domain antigens. Immunoassay kits comprising such antigens are

also provided.

US PAT NO: 5,346,670 :IMAGE AVAILABLE: L14: 24 of 26
 DATE ISSUED: Sep. 13, 1994
 TITLE: Phthalocyanine and tetrabenztriazaporphyrin reagents
 INVENTOR: George E. Renzoni, Seattle, WA
 Deborah C. Schindele, Seattle, WA
 Louis J. Theodore, Seattle, WA
 Clifford C. Leznoff, Ontario, Canada
 Karen L. Fearon, Woodinville, WA
 Barry V. Pepich, Seattle, WA
 ASSIGNEE: British Technology Group U.S.A. Inc., Gulph Mills, PA
 (U.S. corp.)
 APPL-NO: 07/895,601
 DATE FILED: Jun. 8, 1992
 ART-UNIT: 187
 PRIM-EXMR: Amelia Burgess Yarbrough
 LEGAL-REP: Christensen, O'Connor, Johnson & Kindness

US PAT NO: 5,346,670 :IMAGE AVAILABLE: L14: 24 of 26

ABSTRACT:

Red-shifted, water-soluble, fluorescent, monomerically-tetherable derivatives having the formula: ##STR1## wherein, M represents either H.sub.2 or is selected from among the following metals: aluminum, silicon, phosphorus, gallium, germanium, cadmium, scandium, magnesium, tin, and zinc. Each R.sub.1 is independently selected from --XYW, --YW, and --W. X represents either a carbon, or heteroatom selected from among oxygen, nitrogen, sulfur, phosphorus, silicon, and selenium; Y represents a linking group; and W represents a water solubilizing group. The substituent R.sub.2 is selected from among --A, --Y'A, --XA, and --XY'A, where A denotes a biological entity such as an antibody, antibody fragment, nucleotide, **nucleic acid probe**, antigen, **oligonucleotide**, deoxynucleotide, dideoxynucleotide, avidin, streptavidin or membrane probe, or R.sub.2 is a reactive or activatable group suitable for conjugating to a biological entity. Y' is a linking group that tethers the biological entity to the phthalocyanine or tetrabenztriazaporphyrin macrocycle. Z is either a nitrogen atom or a carbon substituted with hydrogen, alkyl, aryl, or aralkyl groups. Z may also be attached to R.sub.2. Also disclosed are derivatives of the compounds of the above Formula in which 1-4 of the benzo ring(s) contain 1 or 2 N atoms. Methods of sequencing **DNA** and detecting analytes, including **cells**, using these derivatives are disclosed, as are kits for carrying out assays for the analytes and flow cytometry. Methods of detecting **DNA** using cationic compounds of the above Formula, wherein R.sub.2 =R.sub.1 and W=-N.sup.+ D.sub.1 D.sub.2 D.sub.3 are also disclosed. Further, compounds containing Tc, Gd, etc. as the metal in the above Formula may be used for **imaging** or therapy.

US PAT NO: 5,283,255 :IMAGE AVAILABLE: L14: 25 of 26
 DATE ISSUED: Feb. 1, 1994
 TITLE: Wavelength-specific cytotoxic agents
 INVENTOR: Julia G. Levy, Vancouver, Canada
 David Dolphin, Vancouver, Canada
 Jack J. Chow, Vancouver, Canada
 Ethan Sternberg, Vancouver, Canada

ASSIGNEE: The University of British Columbia, Vancouver, Canada
(foreign corp.)
APPL-NO: 07/943,895
DATE FILED: Sep. 11, 1992
ART-UNIT: 129
PRIM-EXMR: Richard L. Raymond
LEGAL-REP: Morrison & Foerster

US PAT NO: 5,283,255 :IMAGE AVAILABLE: L14: 25 of 26

ABSTRACT:

A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, **cells** and tissues generally to destroy unwanted **targets**. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to **ligands** specific for receptor or to specific immunoglobulins or fragments thereof to **target** specific tissues or **cells** for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.

US PAT NO: 5,057,313 :IMAGE AVAILABLE: L14: 26 of 26
DATE ISSUED: Oct. 15, 1991
TITLE: Diagnostic and therapeutic antibody conjugates
INVENTOR: Lisa B. Shih, Cedar Grove, NJ
Frederick J. Primus, Potomac, MD
Milton D. Goldenberg, Short Hills, NJ
ASSIGNEE: The Center for Molecular Medicine and Immunology, Newark,
NJ (U.S. corp.)
APPL-NO: 07/309,204
DATE FILED: Aug. 23, 1988
ART-UNIT: 189
PRIM-EXMR: Jeffrey E. Russel
ASST-EXMR: Kay Kim
LEGAL-REP: Foley & Lardner

US PAT NO: 5,057,313 :IMAGE AVAILABLE: L14: 26 of 26

ABSTRACT:

The present invention relates to conjugates of diagnostic or therapeutic principles, such as drugs, toxins, **chelators**, boron compounds and detectable labels, to an antibody, in which the diagnostic or therapeutic principle is first loaded onto a **polymer** carrier such as an aminodextran or a polypeptide of at least 50 amino acids in length, and this intermediate is in turn site-specifically conjugated to a **targeting** antibody such as an antitumor antibody. The resultant conjugate substantially retains the immunoreactivity of the antibody, and **targets** the diagnostic or therapeutic principle to a **target** tissue or organ where the diagnostic or therapeutic effect is realized.

=> log y

U.S. Patent & Trademark Office LOGOFF AT 15:31:19 ON 03 FEB 1998

